STOCK TITAN
  1. Home
  2. Sec-filings
  3. CCCC
  4. [SCHEDULE 13G/A] C4 Therapeutics, Inc. SEC Filing

[SCHEDULE 13G/A] C4 Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock CCCC logo
C4 Therapeutics, Inc.

NASDAQ:CCCC

CCCC Rankings

#6055 Ranked by Market Cap
N/A Ranked by Dividends

CCCC Latest News

May 7, 2025
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Feb 27, 2025
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Feb 24, 2025
C4 Therapeutics to Participate in Upcoming March Investor Conferences
Jan 14, 2025
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
Jan 8, 2025
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CCCC Latest SEC Filings

Jul 15, 2025
[Form 4/A] C4 Therapeutics, Inc. Amended Insider Trading Activity
Jul 14, 2025
[Form 4] C4 Therapeutics, Inc. Insider Trading Activity
Jul 2, 2025
[Form 4] C4 Therapeutics, Inc. Insider Trading Activity
Jul 2, 2025
[Form 4] C4 Therapeutics, Inc. Insider Trading Activity
Jun 20, 2025
[Form 4] C4 Therapeutics, Inc. Insider Trading Activity

CCCC Stock Data

143.43M
56.97M
11.51%
91.51%
12.04%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
WATERTOWN